bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: D N O S A J J M A M F J
2016: D

 
  Other news for:
Liver
 Resources from HONselect
Stivarga Approved for Liver Cancer
First approved treatment for this disease in years

By Scott Roberts

THURSDAY, April 27, 2017 (HealthDay News) -- U.S. Food and Drug Administration approval of the anti-cancer drug Stivarga (regorafenib) has been expanded to include liver cancer, the agency said Thursday in a news release.

Stivarga, among a class of drugs called kinase inhibitors, is designed to block enzymes that foster cancer growth. It's the first drug approved to treat liver cancer in nearly a decade, the FDA said.

"Limited treatment options are available for patients with liver cancer," said Dr. Richard Pazdur, acting director of the agency's Office of Hematology and Oncology Products. The drug was approved for people with liver cancer treated previously with the drug sorafenib.

More than 40,000 people in the United States are projected to be diagnosed this year with liver cancer, and nearly 29,000 will die from it, the National Cancer Institute estimates.

Stivarga is already FDA approved to treat colorectal cancer and gastrointestinal stromal tumors, the agency said.

The drug's effectiveness for treating liver cancer was evaluated in clinical studies of 573 people whose tumors had progressed despite being given sorafenib. The most common side effects included gastrointestinal and abdominal pain, skin reactions, fatigue, diarrhea, loss of appetite, high blood pressure and infection. More serious risks included liver damage, heavy bleeding, gastrointestinal ulcers and problems with blood flow to the heart.

Women who are pregnant or breastfeeding shouldn't take Stivarga, the FDA said. And both genders of child-bearing age who take the drug should use contraception, the agency added.

Approval of Stivarga was granted to Bayer HealthCare Pharmaceuticals, based in Whippany, N.J.

More information

Visit the FDA to learn more.

SOURCE: April 27, 2017, news release, U.S. Food and Drug Administration

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=722132

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Liver
Liver Neoplasms
Therapeutics
Blood
Infection
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Inicio img Sobre nosotros img Rincón de la prensa img Boletín HON img Mapa del sitio img Política ética img Contactos